MINI REVIEW ARTICLE
Front. Immunol., 05 August 2013 | doi: 10.3389/fimmu.2013.00229
Immune parameters to consider when choosing T-cell receptors for therapy
- 1Human Immunity Laboratory and Cellular Immunology Laboratory, Queensland Institute of Medical Research, Brisbane, QLD, Australia
- 2School of Medicine, The University of Queensland, Brisbane, QLD, Australia
- 3Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales, UK
T-cell receptor (TCR) therapy has arrived as a realistic treatment option for many human diseases. TCR gene therapy allows for the mass redirection of T-cells against a defined antigen while high affinity TCR engineering allows for the creation of a new class of soluble drugs. However, deciding which TCR blueprint to take forward for gene therapy or engineering is difficult. More than one quintillion TCR combinations can be generated by somatic recombination and we are only now beginning to appreciate that not all are functionally equal. TCRs can exhibit high or low degrees of HLA-restricted cross-reactivity and alloreact against one or a combination of HLA alleles. Identifying TCR candidates with high specificity and minimal cross-reactivity/alloreactivity footprints before engineering is obviously highly desirable. Here we will summarize what we currently know about TCR biology with regard to immunoengineering.
Keywords: T-cell epitope, T-cell receptor, T-cell engineering
Citation: Burrows SR and Miles JJ (2013) Immune parameters to consider when choosing T-cell receptors for therapy. Front. Immunol. 4:229. doi: 10.3389/fimmu.2013.00229
Received: 11 May 2013; Accepted: 22 July 2013;
Published online: 05 August 2013.
Published online: 05 August 2013.
Edited by:
Bruno Laugel, Cardiff University School of Medicine, UK
Reviewed by:
Liisa Kaarina Selin, University of Massachusetts Medical School, USAMirjam Heemskerk, Leiden University Medical Center, Netherlands
Copyright: © 2013 Burrows and Miles. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: John J. Miles, Human Immunity Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia e-mail: john.miles@qimr.edu.au
No comments:
Post a Comment